Rilematovir
- Generic Name
- Rilematovir
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClF3N4O3S
- CAS Number
- 1383450-81-4
- Unique Ingredient Identifier
- NQ99E8OH3P
- Background
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT05155007
- Locations
- ๐ง๐ช
Clinical Pharmacology Unit, Merksem, Belgium
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT04978337
- Locations
- ๐บ๐ธ
Pines Care Research Center Inc, Pembroke Pines, Florida, United States
๐บ๐ธRenovatio Clinical, The Woodlands, Texas, United States
๐บ๐ธFrontier Clinical Research, Morgantown, West Virginia, United States
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
- Conditions
- Respiratory Tract Infections
- Interventions
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04583280
- Locations
- ๐บ๐ฆ
MNPE City Children's Clinical Hospital โ 6 of Dnipro City Council, Dnipro, Ukraine
๐บ๐ฆME 'Dnipropetrovsk Regional Children's Clinical Hospital of Dnipropetrovsk Regional Council', Dnipro, Ukraine
๐บ๐ฆKharkiv National Medical University on based CHPI Kharkiv Municipal Clinical Children's Hospital 16, Kharkiv, Ukraine
A Study of JNJ-53718678 in Participants With Hepatic Impairment
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT04332523
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธThe Texas Liver Institute, San Antonio, Texas, United States
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
- Conditions
- Respiratory Syncytial Virus
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Janssen Sciences Ireland UC
- Registration Number
- NCT04221412
A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04090086
- Locations
- ๐ณ๐ฑ
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 246
- Registration Number
- NCT03656510
- Locations
- ๐ช๐ธ
Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain
๐ธ๐ชBarn- Och Ungdomsmedicin, Malmรถ, Sweden
๐ธ๐ชSachsska barn-och ungdomssjukhuset, Stockholm, Sweden
A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT03002779
- Locations
- ๐ณ๐ฑ
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT02945007
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02729467
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.